Revenue (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the approximate percentage of our net sales by market group:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
Biologics	41 %	40 %	42 %	40 %
Generics	18 %	18 %	18 %	17 %
Pharma	24 %	24 %	24 %	24 %
Contract-Manufactured Products	17 %	18 %	16 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
High-Value Product Components	54 %	55 %	56 %	54 %
High-Value Product Delivery Devices	6 %	5 %	5 %	4 %
Standard Packaging	23 %	22 %	23 %	23 %
Contract-Manufactured Products	17 %	18 %	16 %	19 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by geographic location:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
Americas	53 %	45 %	48 %	45 %
Europe, Middle East, Africa	38 %	45 %	43 %	45 %
Asia Pacific	9 %	10 %	9 %	10 %
	100 %	100 %	100 %	100 %

Schedule of Change in Contract with Customer, Asset and Liability

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:

	($ in millions)
Contract assets, December 31, 2021	$	14.6
Contract assets, September 30, 2022	18.3
Change in contract assets - increase (decrease)	$	3.7
Deferred income, December 31, 2021	$	(61.3)
Deferred income, September 30, 2022	(52.0)
Change in deferred income - decrease (increase)	$	9.3